Related Experiment Video

Updated: Apr 15, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Checkpoint inhibitors in the treatment of cutaneous malignant melanoma

Jose Lutzky1

  • 1Melanoma Program, Division of Hematology/Oncology, Mount Sinai Comprehensive Cancer Center, Miami Beach, FL 33140, USA. Jose.Lutzky@msmc.com.

Chinese Clinical Oncology
|April 6, 2015
PubMed

Insights

Advanced melanoma is now treatable with immunotherapy. New monoclonal antibody drugs targeting CTLA-4, PD-1, and PD-L1 harness the immune system to fight cancer, changing treatment standards.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Advanced malignant melanoma was historically lethal.
  • Recent research revealed melanoma's molecular alterations and immune evasion tactics.
  • Understanding immune synapse signaling is key.

Purpose of the Study:

  • To review key immunotherapeutic agents for advanced melanoma.
  • To discuss clinical data supporting immunotherapy's efficacy.
  • To highlight the paradigm shift in melanoma treatment.

Main Methods:

  • Review of clinical trial data for immunotherapies.
  • Analysis of monoclonal antibodies targeting immune checkpoints.
  • Focus on agents modulating CTLA-4, PD-1, and PD-L1.

Main Results:

  • Positive outcomes in clinical trials utilizing immunotherapy.
  • Immunotherapy has become a standard treatment for advanced melanoma.
  • Significant progress in understanding melanoma immune evasion.

Conclusions:

  • Immunotherapy represents a major advancement in treating advanced melanoma.
  • Modulating immune checkpoints offers a viable therapeutic strategy.
  • Ongoing research continues to refine melanoma treatment paradigms.
Keywords:
MelanomaPD-1 PDL1cytotoxic T lymphocyte antigen-4 (CTLA-4)immunotherapy checkpoint modulation

More Related Videos

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

6.2K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K